Overall, we suggest that the PAs described in this study can be used as a basis for identification of drugs that potentially can be applied for the treatment of prion and other neurodegenerative diseases that benefit from inhibition of toxic or enhancement of protective functions of PrP or PrP fragments. The gene discussed is PRNP; the disease is neurodegenerative disease.